Amplyx Pharmaceuticals has dosed the first patient in a Phase II clinical trial to assess the efficacy and safety of APX001 to treat infections caused by candida.
Amplyx will examine both the intravenous therapy (IV) and oral APX001 as part of the open-label, single-arm trial.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study drug will be evaluated as a first-line treatment for candidemia, including suspected or confirmed antifungal-resistant cases in non-neutropenic patients.
Up to 20 adult patients are expected to be enrolled at sites in the US and worldwide.
The trial’s primary objective is treatment success at end of study treatment (EOST) as determined by the Data Review Committee (DRC).
Its secondary objectives include time to first negative blood culture, percentage of patients with mycological outcomes at end of study treatment (EOST) and end of treatment (EOT).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAmplyx Pharmaceuticals president and CEO Ciara Kennedy said: “Initiating our Phase II programme for APX001 represents a significant milestone for Amplyx and for patients.
“We anticipate this trial will validate our robust preclinical and Phase I data and demonstrate clinical proof-of-concept for APX001 as a novel treatment for patients with difficult-to-treat and often deadly candida infections.”
Candidemia often leads to morbidity and mortality in the health care setting.
APX001 has shown a broad range of in vitro and in vivo activity against candida, aspergillus and rare moulds, including species that are intrinsically resistant to antifungal drugs.
